Cargando…

Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity

Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Bryan A., Hage, Adam, Kalveram, Birte, Mears, Megan, Plante, Jessica A., Rodriguez, Sergio E., Ding, Zhixia, Luo, Xuemei, Bente, Dennis, Bradrick, Shelton S., Freiberg, Alexander N., Popov, Vsevolod, Rajsbaum, Ricardo, Rossi, Shannan, Russell, William K., Menachery, Vineet D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819921/
https://www.ncbi.nlm.nih.gov/pubmed/31462558
http://dx.doi.org/10.1128/JVI.01282-19
_version_ 1783463843250307072
author Johnson, Bryan A.
Hage, Adam
Kalveram, Birte
Mears, Megan
Plante, Jessica A.
Rodriguez, Sergio E.
Ding, Zhixia
Luo, Xuemei
Bente, Dennis
Bradrick, Shelton S.
Freiberg, Alexander N.
Popov, Vsevolod
Rajsbaum, Ricardo
Rossi, Shannan
Russell, William K.
Menachery, Vineet D.
author_facet Johnson, Bryan A.
Hage, Adam
Kalveram, Birte
Mears, Megan
Plante, Jessica A.
Rodriguez, Sergio E.
Ding, Zhixia
Luo, Xuemei
Bente, Dennis
Bradrick, Shelton S.
Freiberg, Alexander N.
Popov, Vsevolod
Rajsbaum, Ricardo
Rossi, Shannan
Russell, William K.
Menachery, Vineet D.
author_sort Johnson, Bryan A.
collection PubMed
description Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo. Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection. IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment.
format Online
Article
Text
id pubmed-6819921
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-68199212020-04-24 Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity Johnson, Bryan A. Hage, Adam Kalveram, Birte Mears, Megan Plante, Jessica A. Rodriguez, Sergio E. Ding, Zhixia Luo, Xuemei Bente, Dennis Bradrick, Shelton S. Freiberg, Alexander N. Popov, Vsevolod Rajsbaum, Ricardo Rossi, Shannan Russell, William K. Menachery, Vineet D. J Virol Vaccines and Antiviral Agents Enteric viruses exploit bacterial components, including lipopolysaccharides (LPS) and peptidoglycan (PG), to facilitate infection in humans. Because of their origin in the bat enteric system, we wondered if severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle East respiratory syndrome CoV (MERS-CoV) also use bacterial components to modulate infectivity. To test this question, we incubated CoVs with LPS and PG and evaluated infectivity, finding no change following LPS treatment. However, PG from Bacillus subtilis reduced infection >10,000-fold, while PG from other bacterial species failed to recapitulate this. Treatment with an alcohol solvent transferred inhibitory activity to the wash, and mass spectrometry revealed surfactin, a cyclic lipopeptide antibiotic, as the inhibitory compound. This antibiotic had robust dose- and temperature-dependent inhibition of CoV infectivity. Mechanistic studies indicated that surfactin disrupts CoV virion integrity, and surfactin treatment of the virus inoculum ablated infection in vivo. Finally, similar cyclic lipopeptides had no effect on CoV infectivity, and the inhibitory effect of surfactin extended broadly to enveloped viruses, including influenza, Ebola, Zika, Nipah, chikungunya, Una, Mayaro, Dugbe, and Crimean-Congo hemorrhagic fever viruses. Overall, our results indicate that peptidoglycan-associated surfactin has broad viricidal activity and suggest that bacteria by-products may negatively modulate virus infection. IMPORTANCE In this article, we consider a role for bacteria in shaping coronavirus infection. Taking cues from studies of enteric viruses, we initially investigated how bacterial surface components might improve CoV infection. Instead, we found that peptidoglycan-associated surfactin is a potent viricidal compound that disrupts virion integrity with broad activity against enveloped viruses. Our results indicate that interactions with commensal bacterial may improve or disrupt viral infections, highlighting the importance of understanding these microbial interactions and their implications for viral pathogenesis and treatment. American Society for Microbiology 2019-10-29 /pmc/articles/PMC6819921/ /pubmed/31462558 http://dx.doi.org/10.1128/JVI.01282-19 Text en Copyright © 2019 American Society for Microbiology. This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Vaccines and Antiviral Agents
Johnson, Bryan A.
Hage, Adam
Kalveram, Birte
Mears, Megan
Plante, Jessica A.
Rodriguez, Sergio E.
Ding, Zhixia
Luo, Xuemei
Bente, Dennis
Bradrick, Shelton S.
Freiberg, Alexander N.
Popov, Vsevolod
Rajsbaum, Ricardo
Rossi, Shannan
Russell, William K.
Menachery, Vineet D.
Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
title Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
title_full Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
title_fullStr Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
title_full_unstemmed Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
title_short Peptidoglycan-Associated Cyclic Lipopeptide Disrupts Viral Infectivity
title_sort peptidoglycan-associated cyclic lipopeptide disrupts viral infectivity
topic Vaccines and Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819921/
https://www.ncbi.nlm.nih.gov/pubmed/31462558
http://dx.doi.org/10.1128/JVI.01282-19
work_keys_str_mv AT johnsonbryana peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT hageadam peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT kalverambirte peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT mearsmegan peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT plantejessicaa peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT rodriguezsergioe peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT dingzhixia peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT luoxuemei peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT bentedennis peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT bradricksheltons peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT freibergalexandern peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT popovvsevolod peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT rajsbaumricardo peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT rossishannan peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT russellwilliamk peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity
AT menacheryvineetd peptidoglycanassociatedcycliclipopeptidedisruptsviralinfectivity